Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction Treatment of Choice or Is Discretion the Better Part of Valor?⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Intervention or the American College of Cardiology. by Rihal, Charanjit S.
ED
S
M
T
t
C
R
T
n
t
o
t
e
p
f
t
S
m
P
c
I
I
p
c
u
i
m
p
l
t
T
i
t
w
S
r
P
G
S
a
o
P
P
d
r
m
C
fl
r
D
c
d
r
m
r
c
n
D
t
w
(
r
i
R
P
A
p
1
c
0
T
C
t
0
d
D
c
l
e
b
e
*
a
t
L
f
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 , N O . 3 , 2 0 0 8
© 2 0 0 8 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 8 / $ 3 4 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 8 . 0 4 . 0 0 1DITORIAL COMMENT
rug-Eluting Stents for
T-Segment Elevation
yocardial Infarction
reatment of Choice or Is Discretion
he Better Part of Valor?*
haranjit S. Rihal, MD, MBA, FACC
ochester, Minnesota
he use of drug-eluting stents (DES) for primary percuta-
eous coronary intervention (PCI) for ST-segment eleva-
ion myocardial infarction (STEMI) has generated a variety
f responses ranging from enthusiasm to consternation. In
his issue of JACC: Cardiovascular Interventions, Shishehbor
t al. (1) present observational outcome data on 699 STEMI
atients treated with primary PCI at the Cleveland Clinic
rom 2002 to 2007. The clinical and angiographic charac-
eristics of the cohort are typical of a North American
TEMI population, with a mean age about 60 years,
ajority male, 40% smokers, and about 20% diabetic.
See page 227
atients were treated with standard regimens of aspirin,
lopidogrel, unfractionated heparin, and glycoprotein IIb/
IIa inhibitors. Pre-procedural Thrombolysis In Myocardial
nfarction (TIMI) flow grade 3 was present in 31%, and
ost-procedural TIMI flow grade 3 was achieved in 96% of
ases overall. Two types of multivariable adjustment were
sed to address the inherent limitations of the nonrandom-
zed design: Cox multivariable proportional hazards adjust-
ent and propensity analysis of a matched subset of 480
atients. Both analyses indicated that mortality and target
esion revascularization (TLR) were less frequent in patients
reated with DES, almost entirely because of a reduction in
LR. Information regarding recurrent nonfatal myocardial
nfarction is not available, nor is the incidence of stent
hrombosis. While encouraging, without these safety data it
ould be premature to conclude that DES are preferred for
TEMI.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ion or the American College of Cardiology.
From the Department of Medicine and the Director, Cardiac Catheterizationd
aboratory, Mayo Clinic, Rochester, Minnesota. Dr. Rihal received research support
rom Medtronic and is a consultant for Cordis.This important article raises a number of questions
egarding the safety and efficacy of DES usage for primary
CI.
oals of Primary PCI
implistically, the goal of primary PCI is to achieve rapid
nd complete myocardial reperfusion, which in turn leads to
ptimal patient outcomes. Both the technical aspects of the
CI itself as well as efficient organization and delivery of
CI must be optimal. In the Sishehbour series, median
oor-to-balloon time was 109 min, with an interquartile
ange of 40 to 278 min; clearly there is room for improve-
ent even in expert institutions such as the Cleveland
linic. Although balloon angioplasty can establish TIMI
ow grade 3, bare-metal stents (BMS) reduce the risk of
eocclusion or reinfarction after primary PCI. In addition,
ES promise improved late angiographic and clinical out-
omes. Concerns over late stent thrombosis put a significant
amper on enthusiasm for DES in the U.S. in 2007 and
aised cautionary flags regarding the use of these complex
edical devices in STEMI patients.
Because neither randomized nor registry data suggest a
eduction in death or myocardial infarction for DES in
omparison with BMS, it begs the question whether reste-
osis is a worthy consideration at the time of primary PCI.
ata from the Cleveland and Mayo Clinics would suggest
hat it indeed is because a significant minority of patients
ith restenosis present with acute coronary syndromes
ACS) including recurrent myocardial infarction and most
equire hospitalization for repeat procedures with their
nherent cost, morbidity, and mortality (2,3).
andomized and Registry Stent Comparisons in
rimary PCI
meta-analysis of 8 randomized trials involving 2,786
atients compared DES and BMS in STEMI patients with
to 2 years of follow-up (4). Drug-eluting stents signifi-
antly reduced the risk of reintervention (hazard ratio [HR]
.38, 95% confidence interval [CI] 0.29 to 0.50, p 0.001).
he overall incidence of stent thrombosis (HR 0.80, 95%
I 0.46 to 1.39, p  0.43), death (HR 0.76, 95% CI 0.53
o 1.10, p 0.14), and recurrent myocardial infarction (HR
.72, 95% CI 0.48 to 1.08, p  0.11) was not significantly
ifferent for patients receiving DES versus BMS (4).
These data strongly support the safety and efficacy of
ES in STEMI. Despite their advantages for efficacy
omparisons, randomized controlled trials have inherent
imitations of generalizability because of strict inclusion and
xclusion criteria, and the fact patients must be eligible for
oth treatments. Registry data, on the other hand, usually
ncompass a much greater variety of patients and can
ocument outcomes of all comers. In this regard, data from
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234he Thoraxcenter showed less TLR with DES but at a cost of
ore stent thromboses. The TLR benefit eroded with time,
nd after 3 years of follow-up was no longer significant (5).
A so-called real world registry can also reveal the influ-
nce of real world biases and perception in influencing stent
hoice. This trend may be evident in the Cleveland Clinic
rticle, in which utilization of DES for primary PCI
ocketed to about 75% of cases after commercial availability
n March 2003, and then plummeted to only 15% in 2007,
dramatic turnaround. The reasons for this rapid shift from
xtreme enthusiasm to extreme caution are unclear, but
erve to remind us of the myriad of factors that influence
linical practice.
heoretic and Practical Issues With DES in STEMI
ven if one accepts that DES are both safe and effective for
rimary PCI, the task of the interventional cardiologists is
ot simple. Patient education and informed consent, par-
icularly with regard to subtle and important issues such as
ate thrombosis, can be challenging in the best of circum-
tances. In the acute setting, with the JCAHO, CMS, and
ospital quality committees scorecarding of our every move
nd monitoring door to balloon times, it can be extremely
ifficult to assess the potential for compliance with expen-
ive and prolonged antiplatelet regimens. It can be impos-
ible if the patient is sedated, in shock, or intubated. In such
ircumstances, late TLR falls off as a consideration and the
nterventionalist should focus on achieving reperfusion with
s few complicating factors as possible. If there is any doubt
bout the ability of the patient to comply with the usual
edical regimens, then discretion may be the better part of
alor during an acute procedure.
Thrombus is a near-universal finding in STEMI, and
ay lead to an unpredictable therapeutic effect when a DES
s used. Thrombus trapped between the artery and ablumi-
al surface of the stent can reduce uptake up to 10-fold,
hereas clot overlying the stent can shield the drug from
ashout, thereby increasing uptake into the vessel wall (6).
hether such interactions will influence arterial healing
uch that clinically important differences in cardiac events
ill emerge remains to be seen.
To summarize, currently available randomized and ob-
ervational data point to the safety and efficacy of DES in
TEMI but with several caveats and points of emphasis.
irst, DES do not lower acute or long-term mortality in
omparison with BMS. Second, in most patients DES will
ead to superior long-term clinical and angiographic results.
hird, if an operator uses a BMS for STEMI, this should
ot be regarded as a failure, particularly if compliance and
omorbidity are difficult to assess. Two further pieces of
nformation are needed to clinch the role of DES in
TEMI: long-term safety data based on large numbers of
atients and large prospective randomized controlled trials.urrent and Future Directions
lthough balloon occlusion devices were not proven bene-
cial when used routinely, early results suggest that me-
hanical thrombus removal is a useful adjunct before stent
eployment (7,8). The HORIZONS (Harmonizing Out-
omes With Revascularizations and Stents in Acute Myo-
ardial Infarction) trial is a 3,600-patient prospective ran-
omized controlled trial of STEMI patients comparing
rimary PCI with a paclitaxel-eluting stent or BMS. Results
f the stent comparison arm are due later in 2008. This trial
ill provide important new information in the field but is
nlikely to be the final word because only 1 type of DES is
eing tested.
Long-term outcomes of DES are contingent on patient
ompliance with expensive long-term oral antiplatelet
rugs, and discontinuation (premature or otherwise) of
lopidogrel may be especially hazardous after a STEMI.
esistance to oral antiplatelet drugs is associated with an
ncreased risk of recurrent events after STEMI (9), and
lthough several platelet reactivity assays exist, none are in
idespread use at the present time. Point-of-care assays
alidated with clinical outcomes are needed to identify
atients at high risk of recurrent events and to tailor therapy.
As the next generation of DES becomes available in the
.S., these stents will undoubtedly be used in many patients
ith STEMI, but these stents have not been tested in
rospective STEMI trials. Post-market surveillance will be
ecessary to ensure long-term safety and efficacy for each
tent. Perhaps what is needed to advance the field of
TEMI intervention further is development of the disease-
pecific stent technology. Currently, the same DES are used
or chronic stable angina as are for ACS, STEMI, or
schemic cardiomyopathy with ventricular arrhythmias. Be-
ause the pathobiology of STEMI is inherently different
nd much more complex than stable angina, it makes
ntuitive sense that different stents are needed (10). Indeed,
n abciximab-coated stent has been developed and tested
xtensively in Asia (11). Idealistically, specific DES for
TEMI that promote plaque healing and rapid endotheli-
lization, offer local antiplatelet actions, and modulate left
entricular remodeling are needed. Perhaps that day will not
e far into the future.
eprint requests and correspondence: Dr. Charanjit S. Rihal,
irector, Cardiac Catheterization Laboratory, Mayo Clinic,
00 First Street SW, Rochester, Minnesota 55905. E-mail:
ihal@mayo.edu.
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